Bharat Biotech | Page 3 | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Tuesday
June 10, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
TUESDAY, JUNE 10, 2025

Bharat Biotech

 Bharat Biotech completes volunteer enrollment for Phase 3 clinical trials
Coronavirus chronicle

Bharat Biotech completes volunteer enrollment for Phase 3 clinical trials

"COVAXIN successfully completes Phase 3 clinical trials enrolment of 25,800 volunteers," informed Suchitra Ella Joint Managing Director Bharat Biotech International Limited

Representational image. Picture: Collected
Coronavirus chronicle

Serum Institute, Bharat Biotech pledge smooth Covid-19 vaccine roll-out

Photo: Reuters
Coronavirus chronicle

Indian biotech company says approved Covid shot trials 'honest'

A man rides his motorbike past a parked bus of India's biotechnology company Bharat Biotech outside its office in Hyderabad, India July 3, 2020. REUTERS/Stringer
Coronavirus chronicle

India's Bharat Biotech aims to make 700 mln doses of Covid-19 vaccine in 2021

Addressing a petroleum university’s convocation, Modi said: “Work is being done to nearly double the country’s oil refining capacity in the next five years” Photo: Collected from Twitter
Coronavirus chronicle

India will soon start world’s largest vaccination drive: Narendra Modi 

A medic administers Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), during the Phase- 3 trials at the People's Medical College in Bhopal.(PTI)
Coronavirus chronicle

Indian expert panel recommends Bharat Biotech’s Covaxin for restricted emergency use

Small bottles labelled with "Vaccine" stickers stand near a medical syringe in front of displayed "Coronavirus COVID-19" words in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
Coronavirus chronicle

Ocugen to co-develop Bharat Biotech's Covid-19 vaccine candidate for US

A man rides his motorbike past a parked bus of India's biotechnology company Bharat Biotech outside its office in Hyderabad, India July 3, 2020. REUTERS/Stringer
Coronavirus chronicle

Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech 

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net